{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.2","upperLimit":"65.7","value":"62.44"},{"groupId":"OG001","lowerLimit":"60.2","upperLimit":"66.6","value":"63.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"868"},{"groupId":"OG001","value":"866"}],"units":"Participants"}],"description":"(Completed effective March 19, 2018) Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, will be estimated for each randomized arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-DS HR patients receive post induction age-adjusted intrathecal (IT) methotrexate (MTX)","id":"OG000","title":"Non-DS HR B-ALL Arm A"},{"description":"Non-DS HR patients receive post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone","id":"OG001","title":"Non-DS HR B-ALL Arm B"}],"paramType":"NUMBER","populationDescription":"Patients risk assigned as HR B-ALL and randomized to the two post induction therapies (includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"Up to 10 years","title":"Toxicity and Tolerability of Post-induction Age-adjusted ITT Compared to Age-adjusted IT MTX in Children With HR B-ALL","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}